Trials / Completed
CompletedNCT00219297
Study of Patupilone in Patients With Brain Metastasis From Non-small Cell Lung Cancer
An Open-label, Multi-center, Phase II Study to Evaluate the Activity of Patupilone (EPO906), in the Treatment of Recurrent or Progressive Brain Metastases in Patients With Non-small Cell Lung Cancer.
- Status
- Completed
- Phase
- Phase 2
- Study type
- Interventional
- Enrollment
- 50 (actual)
- Sponsor
- Novartis Pharmaceuticals · Industry
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
The study objective is to evaluate the safety and efficacy of patupilone with respect to early progression and response of patients with non-small cell lung cancer (NSCLC) metastatic to the brain, who have progressed after chemotherapy, surgery and/or radiation.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Patupilone |
Timeline
- Start date
- 2005-11-16
- Primary completion
- 2010-06-24
- Completion
- 2010-06-24
- First posted
- 2005-09-22
- Last updated
- 2021-02-21
Locations
12 sites across 1 country: United States
Source: ClinicalTrials.gov record NCT00219297. Inclusion in this directory is not an endorsement.